$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
来那替尼是HER2药物中靶点最为广泛的一类药物
2025-10-19 11:44:20
Check Details
瑞宁得适用于绝经后妇女的晚期乳腺癌的治疗
2025-10-19 11:44:20
Check Details
瑞宁得治疗绝经后激素受体阳性的乳腺癌患者有着显著的效果
2025-10-19 11:44:20
Check Details
瑞宁得可以显著降低乳腺癌患者术后两大复发高峰及四大复发风险
2025-10-19 11:44:20
Check Details
来那替尼治疗晚期乳腺癌的效果数据
2025-10-19 11:44:20
Check Details
瑞宁得治疗绝经后乳腺癌的安全性和有效性
2025-10-19 11:44:20
Check Details
HER2阳性乳腺癌患者的希望-来那替尼
2025-10-19 11:44:20
Check Details
瑞宁得对绝经后乳腺癌患者有着相当不错的疗效
2025-10-19 11:44:20
Check Details
乳腺癌用瑞宁得治疗需要吃多长时间?
2025-10-19 11:44:20
Check Details
乳腺癌患者如何正确服用瑞宁得?
2025-10-19 11:44:20
Check Details
靶向药帕博西尼使乳腺癌患者有了新希望!
2025-10-19 11:44:20
Check Details
瑞宁得可有效改善绝经后乳腺癌患者的生存期
2025-10-19 11:44:20
Check Details
1
2
...
8068
8069
8070
8071
8072
8073
8074
...
10233
10234
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Etrasimod for Ulcerative Colitis: 2mg Once Daily, Onset Timeline, and Safety Monitoring
2
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
3
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
4
Post-Enzalutamide mCRPC: HRR/PARP, PSMA Radioligand, and Chemotherapy Sequencing
5
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
6
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
7
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
8
Bedaquiline for Drug-Resistant TB: 24-Week Regimen, Combination Duration, and When to Stop or Extend
9
Acalabrutinib Dosing and Combination Regimens: CLL/SLL, MCL, Safety Adjustments
10
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
11
Bosutinib for Ph+ CML: Indications, Dosing Adjustments, and Hepatic/Renal Safety
12
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks